TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Industry News Articles > Data Compliance or Rejection – Are you ready for September 15th?

Data Compliance or Rejection – Are you ready for September 15th?

Data Compliance or Rejection – Are you ready for September 15th?

Author: Melissa Rapp, Manager for Regulatory Operations North America

Until recently sponsors have been able to submit nonclinical and clinical reports without datasets and without fear of rejection. In less than three months, the agency will begin to enforce their Technical Rejection Criteria for Study Data “FDA plans to implement eCTD validation checks when submissions contain content under modules 4 and 5 beginning September 15, 2021. Submissions which fail this validation will be subject to rejection.” [1] What does this mean for industry and why is it so important to the agency?

Regulatory submissions in previous decades have progressed from the cumbersome and time-consuming paper volume review to electronic document review via computers and eCTD viewers. Such advancements have helped agency reviewers tremendously. The study data requirement seeks to further improve the review process as it aids the agency with organizational data tools. The advantage of using data standards for review is beneficial in several ways. “Having standard, uniform study data enables FDA scientists to explore many new research questions by combining data from multiple studies. Data standards also help FDA receive, process, review, and archive submissions more efficiently and effectively and the scientists at the FDA. [2] As industry stakeholders, we must keep ahead of the curve for the purpose of achieving important research milestones. A technological hiccup such as a submission rejection can be easily avoided if industry is informed, equipped, and prepared. As the FDA Commissioner Stephen Hahn said in a speech to FDA staff on 30 Jan 2020, “One of the most important resources for our work lies in the power of data. I strongly believe that we need to do everything we can to attain more and better data for the work we’re doing, to be more proactive in gathering data, and to be more creative and thorough in our analysis of it. By harnessing this power, we can improve our regulatory decision-making…” “[3] Understanding the importance of this initiative to the reviewers is motivation for industry to strive towards data standards innovation.

Now that the priority of data standards has been established, the next inquiry into this matter is determining how to achieve compliance.  According to the guidance “Providing Regulatory Submissions in Electronic Format – Standardized Study Data,” NDA, BLA and ANDA submissions with studies that started after Dec. 17, 2016 and Commercial INDs with studies that started after Dec. 17, 2017 are required to be submitted in CDISC format following the FDA Data Standards Catalog “[4]. The agency has already begun to issue warnings like the one below if the correct data has not been submitted along with reports that require them.

3rd Acknowledgment PDF warningThe following is a table that outlines the reports that require datasets and the type of datasets involved.

 

eCTD Technical Rejection Criteria for Study Data Expectations[5]

eCTD Technical Criteria

One prevalent aspect of the table above is the presence of the ts.xpt file. TS.xpt files should be considered as the “gatekeeper” dataset file for nonclinical and clinical study reports. The data provided in these files identifies the categories of data that the agency requires. For example, the ts.xpt file should contain the study start date. In a recent presentation with Pharmalex’s Adair Turner (Director, Regulatory Operations North America), these criteria were explained for a simplified ts.xpt file. The study start date allows FDA to determine that study data is not required to be in a CDISC standardized format. For a simplified ts.xpt file, there should be four variables (STUDYID, TSPARMCD, TSVAL, and TSVALNF) and one row of information.

Table data from DIA RSIDM 2020 FDA Plenary Session  – Technical Rejection Criteria for Study Data by Ethan Chen (OBI – CDER)

Datasets consist of three different file formats. In the image below, the SEND dataset contains a define xml file, a Nonclinical Study Data Reviewer’s Guide in PDF format, and datasets in .xpt format. The define file can be viewed by web-browser in html format. The PDF can be opened by Adobe or any PDF viewer. The .xpt file can be viewed and reviewed in a SAS universal viewer that is available for free download [6]

Data file overview

The amount of information provided and understanding what’s required may appear overwhelming; however, help is available. The agency has provided an “FDA Study Data Prep – Self Checklist”[7] and provides detailed information on their website “Study Data for Submission to CDER and CBER”[8].

 

[1] https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd

[2] https://www.fda.gov/media/98907/download

[3] https://www.raps.org/news-and-articles/news-articles/2020/1/hahn-stresses-importance-of-data-rwe-in-first-all

[4] https://www.fda.gov/regulatory-information/search-fda-guidance-documents/providing-regulatory-submissions-electronic-format-standardized-study-data

[5] DIA RSIDM 2020 FDA Plenary Session  – Technical Rejection Criteria for Study Data by Ethan Chen (OBI – CDER)

[6] https://support.sas.com/downloads/browse.htm?fil=&cat=74

[7] https://www.fda.gov/media/123098/download

[8] https://www.fda.gov/industry/study-data-standards-resources/study-data-submission-cder-and-cber

Related posts
Key Takeaways from the PDA Europe Annex 1 Workshop
Key Takeaways from the PDA Europe Annex 1 Workshop
7th June 2022
NLS DAYS 2022
NLS DAYS 2022
September 28 - May 29th, 2022
Addressing Limitations of Sterility Testing
Addressing Limitations of Sterility Testing
9th May 2022
Are virtual audits sustainable post-pandemic?
Are virtual audits sustainable post-pandemic?
6th May 2022
Orphan Drug Designation: Securing the Significant Benefits
Orphan Drug Designation: Securing the Significant Benefits
28th March 2022
Virtual Audits: To be, or not to be, that is the question
Virtual Audits: To be, or not to be, that is the question
26th January 2022
Search
Upcoming Webinars

June 16th, 2022

Better information, better decisions for your access strategy – Inmediata powered by SmartPHLEX a new platform

2:30 PM CET

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Upcoming Events

June 23rd, 2022

PDA Ireland: Data Integrity

June 19 - 23rd, 2022

DIA 2022 – Reconnect with Your Life Sciences Community Live in Chicago

Visit us at booth #1515

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
8 Jun

Mark A Lane, PhD latest blog here https://lnkd.in/ejDdywz3 explores Integrated Product Development approaches to accelerate drug development.

To find out more register for our IPD webinar https://lnkd.in/eijUBJM5

#pharmadrugdevelopment
#webinar
#biopharmaceutical

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Able to explain technical details so non-experts can understand

    US based small / virtual company
    Partner
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for